Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Carsten Müller-Tidow, MD, Petra Tschanter, MD, Utz Krug, MD, Stefanie Goellner, PhD, Christoph Röllig, MD, Christian Thiede, MD, Anja Koschmieder, Martin Dugas, PhD, Joachim Gerss, PhD, Trude Butterfaß-Bahloul, Ruth Wagner, Stefan W. Krause, MD, Ulrich Kaiser, Volker Kunzmann, MD, Björn Steffen, MD, Richard Noppeney, MD, Wolfgang Herr, MD, Claudia D Baldus, Norbert Schmitz, MD, Katharina Götze, Albrecht Reichle, Martin Kaufmann, MD, Andreas Neubauer, MD, Kerstin Schäfer-Eckart, MD, Mathias Hänel, MD, Rudolf Peceny, MD, Haack Bea, Lilly Meredith, Norbert Frickhofen, MD, Michael G Kiehl, MD, Aristoteles A.N. Giagounidis, MD PhD, Martin Görner, Roland Repp, MD, Ralph Naumann, MD, Hartmut Link, MDPhD, Alexander Kiani, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Hubert Serve, MD, Gerhard Ehninger, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 946.

https://doi.org/10.1182/blood.V124.21.946.946

Published: 2014

Journal Articles

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Ruediger Liersch, Joachim Gerss, Christoph Schliemann, Michael Bayer, Christian Schwöppe, Christoph Biermann, Iris Appelmann, Torsten Kessler, Bob Löwenberg, Thomas Büchner, Wolfgang Hiddemann, Carsten Müller-Tidow, Wolfgang E. Berdel, Rolf Mesters

Blood (2012) 119 (22): 5215–5220.

https://doi.org/10.1182/blood-2011-11-389692

Published: 2012

Includes: Supplemental data

Journal Articles

Anti– Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

Andrea Willer, Joachim Gerß, Thorsten König, Dieter Franke, Hans-Jürgen Kühnel, Günter Henze, Arendt von Stackelberg, Anja Möricke, Martin Schrappe, Joachim Boos, Claudia Lanvers-Kaminsky

Blood (2011) 118 (22): 5774–5782.

https://doi.org/10.1182/blood-2011-07-367904

Published: 2011

Includes: Supplemental data

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

NARROW

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Anti– Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Email alerts

ASH Publications

American Society of Hematology

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Anti– Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only